202212-0289 • 2916 Views • Al/PVC strips. Box of 10 strips x 10 tablets.

Each tablet contains:

Active ingredient:

Cinarizin 25 mg

Cinnarizine is also effective in the control of motion sickness.

Cerebrovascular and Peripheral Cerebral Vascular Disorders.

Disorders of balance - maintenance therapy for symptoms of labyrinthine disorders, including vertigo, tinnitus, nystagmus, nausea and vomiting such as is seen in Meniere's Disease.


Method of administration

For oral use.

Cinnarizine should preferably be taken after meals.


Adults, elderly, and children over 12 years:

25 mg two hours before travel and 15 mg every eight hours during the journey if necessary (in this case, the patient can choose other preparations with more suitable strength).

Cerebrovascular disorders: 75 mg x 1 time/day

Peripheral Vascular Disorders: 75 mg x 2-3 times/day


Hypersensitivity to the active substance or to any of its ingredients.

Porphyrin metabolism disorder


Conditions needing caution when taking the drug

As with other antihistamines, cinnarizine may cause epigastric discomfort; taking it after meals may diminish gastric irritation.

Cinnarizine should only be given to patients with Parkinson's disease if the advantages outweigh the possible risk of aggravating this disease.

There have been no specific studies on hepatic or renal dysfunction. Cinnarizine should be used with care in patients with hepatic or renal insufficiency.

Long-term use of cinnarizine should be avoided in the elderly, because it may cause an increase or appearance of extrapyramidal symptoms, sometimes associated with feelings of depression during prolonged treatment.

Caution should be exercised when high doses of cinnarizine are administered to patients with hypotension because of the potential for hypotension.

Be careful with excipients

Cinnarizine Tablets contain lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency, or glucose-galactose malabsorption should not take this medicine.

The product contains wheat starch, so should not be used by patients allergic to wheat starch (except in cases of celiac disease).

Fertility, pregnancy and lactation


The safety of cinnarizine in human pregnancy has not been established although studies in animals have not demonstrated teratogenic effects. As with other drugs, it is not advisable to administer cinnarizine in pregnancy.


There are no data on the excretion of cinnarizine in human breast milk. Taking cinnarizine whilst breast-feeding is not recommended.

Effects on ability to drive and use machines

Cinnarizine may cause drowsiness, especially at the start of treatment; patients affected in this way should not drive or operate machinery.

Interaction with other medicinal products and other forms of interaction

Drug interactions

Concurrent use of alcohol, CNS depressants or tricyclic antidepressants may potentiate the sedative effects of these drugs or of cinnarizine.

Due to its antihistamine effect, cinarizin may prevent positive skin reaction indicators if this product is taken 4 days before testing.

Drug incompatibility

Since there are no incompatibility studies, this drug should not be mixed with other drugs.

Undesirable effects

Frequencies displayed use the following convention:

Very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to <1/1,000); very rare (<1/10,000) and not known (cannot be estimated from the available data).

System organ class

Frequency category

Adverse drug reactions

Nervous system disorders





Not known

Dyskinesia, extrapyramidal disorder,, Parkinsonism, Tremor

Gastrointestinal disorders


Nausea, indigestion


Vomiting, epigastric abdominal pain

Hepatobiliary disorders

Not known

Cholestatic jaundice

Skin and subcutaneous tissue disorders


Hyperhidrolysis, Lichenoid keratosis including lichen planus

Not known

Subacute cutaneous lupus erythematosus

Musculoskeletal and connective tissue disorders

Not known

Muscle rigidity

General disorders and administrative site conditions




Weight increased

Overdose and Treatment


Acute cinnarizine overdoses have been reported with doses ranging from 90 to 2,250 mg. Alterations in consciousness ranging from somnolence to stupor and coma, vomiting, extrapyramidal symptoms, and hypotonia are the most commonly reported signs and symptoms associated with a cinnarizine overdose. In a small number of young children, seizures developed. Clinical consequences were not severe in most cases, but deaths have been reported after single and polydrug overdoses involving cinnarizine.


Consider using activated charcoal within 1 hour when an overdose of cinarizine (eg, 15 mg/kg) is detected.

There is no specific antidote to cinnarizine and in the event of overdosage, treatment is symptomatic and supportive care.


36 months from the manufacturing date. Do not use this product after the expiry date.


Al/PVC strips. Box of 10 strips x 10 tablets.

Your comment

Similar products

Vỉ Al/PVDC. Hộp 05 vỉ x 10 viên nang cứng
Contact Us
Neuralmin 75
Box of 2 blisters x 14 capsules. Box of 4 blisters x 14 capsules
Contact Us
Box of 4 blisters x 14 capsules
Contact Us
Sentipec 50
Box of 5 blisters x 10 capsules
Contact Us
Box of 10 blisters x 10 hard capsules.
Contact Us
Piroton 400
Box of 5 blisters x 10 capsules.
Contact Us
Piroton 800
 Box of 5 blisters x 10 film-coated tablets.
Contact Us